Cambridge, MA, May 12, 2022– (Business Wire) – Ultivue, Inc., the industry leader in multiplexing access and analytical solutions for tissue biomarker studies, today announced multiple collaborations to create AI-driven spatial solution solutions aimed at translation research and biopharmaceutical groups.
Ultivue Multiplex develops a unique workflow for immunofluorescence (MIF) imaging and spatial phenomics. Its proprietary InSituPlex® technology is designed for rapid and comprehensive search of biologically relevant targets up to 12-plexes with the same H&E analysis slides in valuable tissue samples. The technology combines the power of computational pathology and spatial biology to guide translational science in immuno-oncology.
Image and data analysis from rich spatial data from MIF images can accelerate the discovery and validation of tissue biomarkers. Different abilities are required depending on the scientific question being explored, the size of the teams and the stage of the biomarker development program. Ultivue is dedicated to complementing its own image data services by providing end-to-end support processes to customers with capabilities provided by trusted partners. Flexible image analysis solutions are provided by such Vizioform And Indica Labs Bespoke designed to answer a scientific question can be used effectively to provide rich readouts from MIF access. These solutions can be used in Ultivue, Customer or A. OracleBio, GMP-compliant workflow. Co-marketing agreement with Ignorant, A keen eyeAnd Atomic, Enable Ultivue to offer artificial intelligence solutions that best complement MIF testing for the purpose of efficiently analyzing large groups. Hands-on time per picture and reading continuity can be significantly improved, and the results can be viewed by online viewers – created with a viewer optimized for reading MIF and H&E access on a single slide. Ignorant. Collaborates with Altivue Page To integrate artificial intelligence analysis into clinical workflows, as well Jegami Uses AI to interactively explore large cohort images and analytics data for quality control and scientific interpretation.
All of these agreements allow Ultivue to present biopharmaceutical clients with a seamless workflow that combines the power of MIF and AI development and ensures easy integration of phases with analysis. As Florian Lace, VP of Digital Health Strategies, points out, “Translating science and clinical trials will require different capabilities at different stages to unlock the full potential of MIF and AI. Encouraged to work with trusted partners to complement, we collectively accelerate the journey of our biopharmaceutical clients and allow them to focus on a completely scientific aspect that no player has been able to do on their own.
Ultivue provides researchers and scientists in the field of translational medicine, including multiplex biomarker access for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced search and interrogation of tissue samples for accurate drug research. These highly customizable solutions, combined with our consulting scientific approach, strengthen and accelerate biomarker discovery and drug development programs. To learn more, visit Ultivue.com.
The text of the press release published as a result of translation should not be considered as official in any way. The only authentic version of the press release is in the original language of the press release. The translation must always be compared with the source text, which will set a precedent.
See the source version at businesswire.com: https://www.businesswire.com/news/home/20220512005349/en/
Florian Lace, Ph.D.
Dr. Vice President of Digital Health Strategy